Quality of life maintained on the ziv-aflibercept/FOLFIRI regimen: Third interim analysis of the global aflibercept safety and HR-QOL program.
Julien Taı̈eb(Hôpital Européen Georges-Pompidou), Alberto F. Sobrero(Ospedale Policlinico San Martino), Roberto Bordonaro(Ospedale Garibaldi), Florence Joulain(Sanofi (France)), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Francesco Di Costanzo, Salvatore Siena(University of Milan), Sandrine Brette, Emmanuelle Dochy(Sanofi (Belgium)), Chiara Zilocchi(Sanofi (Italy)), Sarah Naoshy(Sanofi (United States)), Anne Thomas(Leicester Royal Infirmary), Pilar Alfonso, Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Libero Ciuffreda(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Hendrik Kroening, Yan Moore(Sanofi (United States)), Gérard Lledo(American Society of Clinical Oncology), Pascale Garreau-Laporte(Sanofi (France))
Cited by 1
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k